№ files_lp_4_process_2_57766
File format: docx Character count: 5666 File size: 4198 KB
Analysis of acquired ESR1 F404 mutations and their impact on fulvestrant resistance in breast cancer, including clinical cohort outcomes and experimental validation in cell line models.
Year: 2026
Region / City: London, United Kingdom; Urbana, Illinois, USA; New York City, USA; Glasgow, United Kingdom
Topic: Breast cancer, ESR1 mutations, drug resistance
Document Type: Research article
Institution: The Institute of Cancer Research; University of Illinois at Urbana-Champaign; Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College; The Royal Marsden Hospital
Authors: Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J Cutts, Heena Shah, Laura Moretti, Lucy S Kilburn, Hannah Johnson, Iain R Macpherson, Alistair Ring, Judith M Bliss, Yingwei Hou, Weiyi Toy, John A Katzenellenbogen, Sarat Chandarlapaty, Nicholas C Turner
Keywords: Fulvestrant, acquired resistance, ESR1 F404, breast cancer, PIK3CA, TP53, ESR1 D538G, ESR1 E380Q, ESR1 Y537N
Methods: Patient cohort analysis, progression-free survival assessment, CRISPR gene editing, RNA sequencing, clonogenic assays
Target Audience: Oncologists, cancer researchers, molecular biologists
Supplementary Data: Figures 1–9, mutation incidence, gene expression, drug response curves
Clinical Focus: Acquired resistance to fulvestrant in ESR1 mutant breast cancer models
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Ribociclib in combination with fulvestrant for HR+/HER2- advanced or metastatic breast cancer: PBAC July 2020 submission and resubmission
Year: 2020
Regulatory body: Pharmaceutical Benefits Advisory Committee (PBAC)
Region: Australia
Drug: Ribociclib (Kisqali)
Combination therapy: Fulvestrant
Indication: Hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer
Population: Non-premenopausal adults
Clinical trials referenced: MONALEESA-2, MONALEESA-3, BOLERO-2
Treatment line: First-line and second-line therapy
Outcome measures: Progression-free survival, overall survival, overall response rate, adverse events, health-related quality of life
Economic analysis: Cost-minimisation (first-line), cost-effectiveness (second-line)
Submission type: Major submission with minor resubmission for economic model adjustment
Approval status: TGA-approved ribociclib (2017, updated 2020), fulvestrant generic approved 2020
Manufacturer: Novartis Pharmaceuticals Australia Pty Ltd / Sandoz
Date of PBAC meeting: July 2020
NW GLH ctDNA ESR1 Pathway SOP
Year: 2023
Region / City: Manchester
Topic: ctDNA Testing, ESR1 Pathway
Document Type: Standard Operating Procedure
Organization: North West Genomic Laboratory Hub (NWGLH)
Author: Not specified
Target Audience: NHS Trusts, Clinical Teams
Action Period: Ongoing
Approval Date: Not specified
Revision Date: Not specified
S4 Table. General Characteristics and Results of Included Meta-Analyses on the ESR1 G2014A Gene Polymorphism and Osteoporosis Risk
Document section: Supplementary table S4
Subject: ESR1 G2014A gene polymorphism and osteoporosis risk
Academic field: Genetic epidemiology
Type of document: Supplementary scientific table
Study design: Meta-analysis of case–control studies
Population characteristics: Female participants with specified menopausal status
Countries represented: Mexico; Thailand
Geographic regions: South America; East Asia
Ethnicity groups: Mixed; Asian
Control source: Population-based (PB); Hospital-based (HB)
Genetic focus: ESR1 G2014A polymorphism
Variables reported: Genotype distribution; allele distribution; minor allele frequency; Hardy–Weinberg equilibrium p-value
Sample information: Cases and controls with genotype counts (A/A, A/G, G/G)
Total samples reported: 640; 228; 358; 352; 66
Authors cited: Gómez R et al.; Ongphiphadhanakul B et al.; Wajanavisit et al.
Years of referenced studies: 2001; 2003; 2005; 2007; 2015
Topics: F404 fulvestrant ESR1